Objective: This study aimed to assess the usefulness of narrow band UVB (NB-UVB) therapy in Yemeni patients with different skin conditions. Methods: A prospective clinical audit was conducted of 120 Yemeni patients (45 males and 75 females), aged 5-54 years from all patients with different skin diseases in dermatology clinic (January 2013-May 2014), treated by NB-UVB irradiation without being combined with topical steroid or topical chemotherapy during the course of the study. Results: 120 patients enrolled in this study with mean age 25.8±12.6 years old. Females consisted of the major rate (62.5%), and patients who came from Aden had a high rate (77.5%). Ninety four (78.3%) patients had complete response to treatment, 6.7% had partial and 15% had no response. Mycosis fungoid and atopic dermatitis had a high mean number of session (84.50±0.70), followed by vitiligo with mean number of sessions 27.10±23.70. The Lichen planus, Mycosis and Pityriasis had complete response (100%) to treatment, followed by vitiligo 79.3%, while partial response appeared in patients with alopecia (66.7%) and atopic dermatitis (22.2%). Patients with chronic renal failure had no response to treatment in 33.3%, followed by Parapsoriasis (20%). Conclusion: Our study proves that NB-UVB therapy is an effective and safe tool in the management of skin diseases and is considered the first-line phototherapeutic option for many skin conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.